Your browser doesn't support javascript.
loading
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert, Maria-Luisa; Schmitt, Anita; Sellner, Leopold; Neuber, Brigitte; Kunz, Joachim; Wuchter, Patrick; Kunz, Alexander; Gern, Ulrike; Michels, Birgit; Hofmann, Susanne; Hückelhoven-Krauss, Angela; Kulozik, Andreas; Ho, Anthony D; Müller-Tidow, Carsten; Dreger, Peter; Schmitt, Michael.
Affiliation
  • Schubert ML; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Schmitt A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Sellner L; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Neuber B; German Cancer Consortium (DKTK), National Centre for Tumour Diseases (NCT), Heidelberg, Germany.
  • Kunz J; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Wuchter P; Department of Pediatric Hematology, Oncology and Immunology, Children's Hospital, Heidelberg University Hospital, Heidelberg, Germany.
  • Kunz A; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Gern U; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Michels B; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hofmann S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hückelhoven-Krauss A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Kulozik A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Ho AD; Department of Pediatric Hematology, Oncology and Immunology, Children's Hospital, Heidelberg University Hospital, Heidelberg, Germany.
  • Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Dreger P; German Cancer Consortium (DKTK), National Centre for Tumour Diseases (NCT), Heidelberg, Germany.
  • Schmitt M; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
BMJ Open ; 9(5): e026644, 2019 05 19.
Article in En | MEDLINE | ID: mdl-31110096
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / T-Lymphocytes / Immunotherapy, Adoptive / CD28 Antigens / Antigens, CD19 / Cell- and Tissue-Based Therapy / Lymphoma Type of study: Guideline / Observational_studies Aspects: Ethics Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: BMJ Open Year: 2019 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / T-Lymphocytes / Immunotherapy, Adoptive / CD28 Antigens / Antigens, CD19 / Cell- and Tissue-Based Therapy / Lymphoma Type of study: Guideline / Observational_studies Aspects: Ethics Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: BMJ Open Year: 2019 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido